Literature DB >> 1457584

Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.

S Tosti, R Caruso, F D'Adamo, A Picardi, M Ali Ege, G Girelli, F R Mauro, L Maurillo, S Amadori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1457584     DOI： 10.1007/bf01703953

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia.

Authors:  Y Bastion; B Coiffier; C Dumontet; D Espinouse; P A Bryon
Journal:  Ann Oncol       Date:  1992-02       Impact factor: 32.976

2.  Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

Authors:  M J Keating; H Kantarjian; M Talpaz; J Redman; C Koller; B Barlogie; W Velasquez; W Plunkett; E J Freireich; K B McCredie
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

Review 3.  Chronic lymphocytic leukemia: new insights into biology and therapy.

Authors:  K A Foon; K R Rai; R P Gale
Journal:  Ann Intern Med       Date:  1990-10-01       Impact factor: 25.391

4.  A comprehensive phase I and II clinical investigation of fludarabine phosphate.

Authors:  M Grever; J Leiby; E Kraut; E Metz; J Neidhart; S Balcerzak; L Malspeis
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929

Review 5.  Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.

Authors:  M J Keating
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929
  5 in total
  8 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 2.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

Review 5.  Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.

Authors:  Syed Saqib Ali; Ruchika Raj; Tejinder Kaur; Brenna Weadick; Debasis Nayak; Minnsung No; Jane Protos; Hannah Odom; Kajal Desai; Avinash K Persaud; Joanne Wang; Rajgopal Govindarajan
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

Review 6.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Simona Sica; Dimitar G Efremov
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

Review 8.  Autoimmunity in chronic lymphocytic leukemia.

Authors:  J H Ward
Journal:  Curr Treat Options Oncol       Date:  2001-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.